版本:
中国

BRIEF-Catalyst Biosciences says milestone payment received with completion of IND-enabling toxicology studies

April 11 Catalyst Biosciences Inc

* Catalyst Biosciences Inc - milestone payment received with completion of IND-enabling toxicology studies

* Catalyst Biosciences - collaborator, isu abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe Hemophilia B in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐